Koeppler H, Pflueger K H, Seitz R, Havemann K
Department of Internal Medicine, Philipps-University, Marburg, FRG.
Onkologie. 1989 Dec;12(6):277-9. doi: 10.1159/000216662.
Eight patients with advanced malignant melanoma were treated with high-dose melphalan (80-90 mg/m2) and BCNU (600-800 mg/m2). In all patients autologous bone marrow preservation was performed prior to therapy. Bone marrow was stored for 48 h in a refrigerator at 10 degrees C and reinfused 48 h post-therapy. Three patients had a complete response (CR), 1 a partial response and 4 patients no response. Two patients with CR died 4 and 5 months after therapy. One had an interstitial pneumonitis and 1 patient died from unknown cause. The third patient had a relapse 12 months after therapy. Major side effects were severe nausea/vomiting and a mild mucositis. Two patients suffered from BCNU-related encephalopathy. All patients had a full hematologic reconstitution after 6 weeks. High-dose chemotherapy with autologous bone marrow support achieves a high response rate. Long-term disease-free survival, however, was not seen with this approach.
8例晚期恶性黑色素瘤患者接受了大剂量美法仑（80 - 90mg/m²）和卡莫司汀（600 - 800mg/m²）治疗。所有患者在治疗前均进行了自体骨髓保存。骨髓在10摄氏度的冰箱中保存48小时，并在治疗后48小时回输。3例患者完全缓解（CR），1例部分缓解，4例无反应。2例CR患者在治疗后4个月和5个月死亡。1例发生间质性肺炎，1例死因不明。第3例患者在治疗后12个月复发。主要副作用为严重恶心/呕吐和轻度粘膜炎。2例患者出现与卡莫司汀相关的脑病。所有患者在6周后均实现了完全血液学重建。自体骨髓支持下的大剂量化疗取得了较高的缓解率。然而，这种方法未观察到长期无病生存。
